Perhapsthe next generation of prospective, translational research studies will incorporateboth venous and core biopsy sampling at time intervals as an endeavour to discoverprospective and stable circulating biomarkers, such as miRNAs, which may indicatepCR to therapies within HER2/neu overexpressing breast cancer. Here, ERBB2 is linked to breast cancer.